



September 15, 2016

News Release

MSD K.K.
Kyorin Holdings, Inc.

**MSD and Kyorin Sign Agreement on Co-Promotion of Therapeutic Agent
for Allergic Rhinitis, NASONEX[®] Nasal**

MSD K.K. (Head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen, "MSD") and Kyorin Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President & CEO: Mitsutomo Miyashita, Ph.D., "Kyorin"), a wholly owned subsidiary of Kyorin Holdings, Inc. (Head office: Chiyoda-ku, Tokyo; President & CEO: Minoru Hogawa), have signed an agreement regarding the co-promotion of a metered-dose, manual pump spray unit for allergic rhinitis, NASONEX[®] Nasal 50 µg (NASONEX[®]). MSD will continue the manufacturing and marketing of NASONEX[®], and MSD and Kyorin will jointly start co-promotion on November 1, 2016.

NASONEX[®] has been approved and marketed in about 130 countries and regions as a therapeutic agent for seasonal and perennial allergic rhinitis. Among those, about 120 countries and regions, including Japan, have a pediatric indication.

MSD continues accelerating its R&D of innovative medicines based on the latest science in areas including the respiratory/allergy area, maximizing the opportunity of existing respiratory products.

With this agreement, Kyorin will expand its lineup of products in the focus areas (respiratory and otolaryngology) and will take active measures in these areas to enhance its presence.

Contact	
MSD K.K. Communications Kitanomaru Square, 1-13-12, Kudan-Kita Chiyoda-ku, Tokyo 102-8667 Tel: 03-6272-1001 Fax: 03-6238-9136	Kyorin Holdings, Inc. President's Office Corporate Communication 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311 Tel: 03-3525-4707 Fax: 03-3525-4777